Increased <scp> <i>MYBL2</i> </scp> expression in aggressive hormone‐sensitive prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer

Published:2022-10-02 Issue:22 Volume:16 Page:3994-4010
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Yoshikawa Yuki¹²^ORCID,Stopsack Konrad H.¹,Wang Xin Victoria³,Chen Yu‐Hui³,Mazzu Ying Z.¹^ORCID,Burton Foster⁴^ORCID,Chakraborty Goutam⁵,Rajanala Sai Harisha¹,Hirani Rahim¹^ORCID,Nandakumar Subhiksha⁶,Lee Gwo‐Shu Mary⁴,Frank David⁴,Davicioni Elai⁷,Liu Glenn⁸,Carducci Michael A.⁹,Azuma Haruhito²,Kantoff Philip W.¹,Sweeney Christopher J.⁴

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

2. Department of Urology Osaka Medical and Pharmaceutical University Japan

3. ECOG‐ACRIN Biostatistics Center Dana‐Farber Cancer Institute Boston MA USA

4. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA

5. Department of Urology Icahn School of Medicine at Mount Sinai New York NY USA

6. Center for Molecular Oncology Memorial Sloan Kettering Cancer Center New York NY USA

7. Decipher Biosciences Inc. San Diego CA USA

8. University of Wisconsin Carbone Cancer Center Madison WI USA

9. Sidney Kimmel Cancer Center Johns Hopkins Medical Institutions Baltimore MD USA

Funder

U.S. Department of Defense

Prostate Cancer Foundation

National Cancer Institute

ECOG-ACRIN Cancer Research Group

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13314

Reference38 articles.

1. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

3. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

4. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer;Cancer Research Communications;2024-09-01

2. MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer;2024-02-02

3. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data;International Journal of Molecular Sciences;2024-01-11

4. Research Progress on the Association between the MYBL2 Gene and Gynecologic Malignancies;Advances in Clinical Medicine;2024

5. From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies;Cancer and Metastasis Reviews;2023-11-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3